05:38 PM EDT, 05/23/2024 (MT Newswires) -- Blueprint Medicines ( BPMC ) said Thursday that updated Phase 1 dose escalation data show that BLU-222, in combination with ribociclib and fulvestrant, was well-tolerated at clinically active dose level in the study to treat a form of breast cancer.

The company said that as of the cutoff date, no dose-limiting toxicities, treatment-related severe adverse events or treatment discontinuations due to BLU-222 were reported.

"This represents a highly significant milestone and holds promise as an important new cornerstone for the treatment of breast cancer, including in the front-line metastatic setting," Dr. Becker Hewes, chief medical officer at Blueprint Medicines ( BPMC ), said in a statement.

The maximum tolerated combination dose was not identified, and the dose escalation part of the study will continue, the company said.